CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study

Jie-Jing Qian1,2,3 | Xiaoxia Hu4 | Ying Wang5 | Yi Zhang1,2,3 | Juan Du6 | Min Yang1,2,3 | Hongyan Tong1,2,3 | Wen-Bin Qian1,2,3 | Juying Wei1,2,3 | Wenjun Yu1,2,3 | Yin-Jun Lou1,2,3 | Liping Mao1,2,3 | Hai Tao Meng1,2,3 | Liang-Shun You1,2,3 | Libing Wang4 | Xia Li1,2,3 | Xin Huang1,2,3 | Li-Hong Cao7 | Jian-Zhi Zhao8 | Xiao Yan Yan9 | Yu-Bao Chen5 | Yu Chen5 | Su-Jiang Zhang5 | Jie Jin1,2,3 | Jiong Hu10 | Hong-Hu Zhu1,2,3

1Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China
2Institute of Hematology, Zhejiang University, Zhejiang, China
3Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
4Department of Hematology, Institute of Hematology, Shanghai Hospital, Shanghai, China
5Department of Hematology, Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital North, Shanghai, China
6Department of Hematology, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China
7Department of Hematology, Shulan (Hangzhou) Hospital, Hangzhou, China
8Department of Hematology, Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China
9Department of Biostatistics, Peking University Clinical Research Institute, Beijing, China
10Shanghai Institute of Hematology, Department of Hematology, Blood and Marrow Transplantation Center, Collaborative Innovation Center of Hematology, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Abstract

Adult patients with relapsed or refractory T-cell acute lymphoblastic leukemia (R/R-T-ALL) have extremely poor prognosis, representing an urgent unmet medical need. Finding an optimal salvage regimen to bridge transplantation is a priority. The CAG (cytarabine, aclarubicin, and G-CSF) regimen was initially used by one group in China, showing unexpectedly promising results in 11 R/R-T-ALL patients. Here, we report the multicenter results of 41 patients who received the CAG regimen as salvage therapy. After one cycle of the CAG regimen, complete remission and partial remission were achieved in 33 (80.5%) and two (4.9%) patients, respectively. Failure to respond was observed in six patients (14.6%). Early T-cell precursor (ETP) (n = 26) and non-ETP (n = 15) patients had a similar CR rate (80.8% vs 80.0%, P = .95). Among 41 patients, allo-HSCT was successfully performed in 27 (66%) patients (22 in CR and 5 in non-CR). With a median follow-up time of 12 months, the estimated...
1 | INTRODUCTION

Adult T-cell acute lymphoblastic leukemia (T-ALL) accounts for approximately 25% of adult ALL cases and has inferior outcomes. Although the outcomes have improved slowly in recent years for newly diagnosed patients, refractory or relapsed T-ALL (R/R-T-ALL) patients have extremely poor outcomes, with <10% of patients surviving long term. The only curable treatment is initiating a salvage regimen to achieve complete remission (CR) and then rapidly performing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, selecting an effective salvage regimen is vital for R/R-T-ALL.

Until now, there has been no consensus about optimal salvage treatments for R/R-T-ALL, representing an urgent, unmet medical need. Conventional chemotherapy options, such as FLAG (fludarabine, cytarabine, and granulocyte colony-stimulating factor), with or without idarubicin and clofarabine in combination with etoposide and cyclophosphamide, or even the only T-ALL target drug (nelarabine), have been used, but the overall response rates are only 30%-50%. Therefore, a more effective and safer salvage regimen for R/R-T-ALL is highly awaited.

The CAG regimen [cytarabine (C), aclarubicin (A), and granulocyte colony-stimulating factor (G)], which is conventionally used in China in acute myeloid leukemia (AML), showed unexpectedly promising preliminary results for the treatment of R/R-T-ALL in the pilot study performed by the Xue group. In fact, 10 of 11 patients with R/R-T-ALL achieved CR. The limited same size prompted us to further extend the study to validate these results of the CAG regimen for adult R/R-T-ALL.

The CAG regimen [cytarabine (C), aclarubicin (A), and granulocyte colony-stimulating factor (G)], which is conventionally used in China in acute myeloid leukemia (AML), showed unexpectedly promising preliminary results for the treatment of R/R-T-ALL in the pilot study performed by the Xue group. In fact, 10 of 11 patients with R/R-T-ALL achieved CR. The limited same size prompted us to further extend the study to validate these results of the CAG regimen for R/R-T-ALL in a multicenter setting. Here, we report the results of a multicenter study by the Chinese Leukemia Cooperation Group (CLCG) to evaluate the efficacy and safety of the CAG regimen for the treatment of adult R/R-T-ALL.

2 | METHODS

2.1 | Study design and data collection

This was a multicenter (six centers), retrospective analysis. The presence of R/R-T-ALL was confirmed. Eligibility criteria were age 16 years or older, and CAG regimen as salvage therapy from September 2012 to June 2019. The study was conducted in accordance with the Declaration of Helsinki, and approval was granted by the relevant ethics committees.

The CAG regimen (cytarabine, 10 mg/m² subcutaneously every 12 h on days 1-14 or 20 mg/m² subcutaneously every 12 h on days 1-7; aclarubicin, 20 mg intravenously daily on days 1-4; and granulocyte colony-stimulating factor (G-CSF), 200 mg/m² per day subcutaneously from day 1 until neutrophil recovery) was administered. After achieving CR, patients received the same CAG regimen or other regimens as subsequent consolidation and then allo-HSCT as soon as possible if a suitable donor was available.

Early T-cell precursor (ETP) ALL (ETP-ALL) was defined as leukemia characterized by the absence (<5% positive cells) of CD1a and CD8 expression, weak CD5 expression (<75% positive cells), and expression (>25% positive cells) of at least one or more of the following myeloid or stem cell markers: CD117, CD34, human leukocyte antigen (HLA)-DR, CD13, CD33, CD11b, and CD65.

2.2 | Statistical analysis

The measured outcomes were CR, partial response (PR), OS, and event-free survival (EFS). CR was defined as <5% blasts in the bone marrow (BM) with normalization of peripheral blood counts (ANC ≥ 1x10⁹/L and platelet count ≥ 100x10⁹/L) and complete resolution of extramedullary disease. PR was defined similarly, except for the presence of 6 to 25% BM blasts. Relapse was defined as the reappearance of blasts in the blood or in the bone marrow (>5%) or in any other extramedullary site after a CR. Refractory disease was defined as the failure to achieve CR at the end of induction therapy. 25 OS was calculated as the interval between the diagnosis of refractory disease or relapse and death from any cause. EFS was defined as the time between the diagnosis of refractory disease or relapse and the day of the first adverse event (salvage failure, further relapse, or death from any cause). Survival probabilities were analyzed by the Kaplan-Meier method. Outcomes were

2-year overall survival and event-free survival were 68.8% (95% CI, 47.3%-83.0%) and 56.5% (95% CI, 37.1%-71.9%), respectively. The CAG regimen was well-tolerated, and no early death occurred. Our multicenter results show that the CAG regimen is highly effective and safe, representing a novel choice for adult patients with R/R-T-ALL and providing a better bridge to transplantation.

KEYWORDS
refractory or relapse, stem cell transplantation, T-cell acute lymphoblastic leukemia
compared between the different subgroups by the log-rank test. The independence of the categorical parameters was calculated using either a χ² test or Fisher's exact test. The distribution of the continuous variables was calculated using a Mann-Whitney U test. P < .05 were considered significant.

3 | RESULTS

The characteristics of all 41 patients are shown in Figure 1 and Table 1. There were 28 males and 13 females, and the median age was 31 years (range, 15-78 years). The numbers of patients with ETP-ALL and non-ETP-ALL were 26 (63.4%) and 15 (36.6%), respectively. There were 31 (75.6%) primary refractory patients who had undergone 1-3 prior salvage chemotherapy cycles including the VDLP, VDCP, or hyper-cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) regimens, and 10 relapsed patients (24.4%) (3 of 10 patients had undergone 1-2 prior salvage chemotherapy regimens) with a median relapse time of 14.5 months (4-48 months) (Table 1). The last follow-up time was 1 July 2019, and the median follow-up time was 12 months (range, 1-63 months). There were 30 patients alive at the last contact, and 11 patients died of the disease.

As shown in Table 1, after one cycle of the CAG regimen among 41 patients, complete remission and partial remission were achieved in 33 (80.5%) and two (4.9%) patients, respectively. Failure to respond was observed in six patients (14.6%). ETP (n = 26) and non-ETP (n = 15) patients had a similar CR rate (80.8% vs 80.0%, P = .95). No patients experienced an early death within 1 month after the initiation of the CAG regimen. Among 41 patients, allo-HSCT was successfully performed in 27 (66%) patients (22 in CR and 5 in PR/NR), and 24 patients receiving allo-HSCT were still alive at the last follow-up. Thirty-three patients achieved CR after CAG with the intent of being transplanted, and 22 patients actually reached transplantation. Among 22 patients who received allo-HSCT after achieving CR from CAG, 10 patients directly bridged to allo-HSCT without consolidation, eight patients repeated the CAG regimen, and four patients received hyper-CVAD as consolidation before allo-HSCT.

In a total of 41 patients, the estimated 2-year OS was 68.8% (95% CI, 47.3%-83.0%), and the EFS was 56.5% (95% CI, 37.1%-71.9%) (Figure 2). ETP and non-ETP patients had similar OS (78.3% vs 52.1%, respectively, P = .20) and EFS (63.2% vs 45.3%, respectively, P = .42) values (Figure 3).

Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. As shown in Table 2, grade 3 to 4 neutropenia and thrombocytopenia occurred in 30 (73%) and 32 (78%) patients, respectively. The median duration of neutropenia during the first cycle of CAG therapy was 10 days (range 6-28 days). The most common nonhematologic AE was infection (grade 3-4, 58%). The infections that occurred during CAG chemotherapy were in the lung (55.6%), gastrointestinal tract (14.8%), skin (11.1%), bloodstream (11.1%), and unknown locations (7.4%). No cases of grade 3 to 4 nausea, vomiting, diarrhea, thrombosis/embolism, cardiac events, raised creatinine, or nervous system symptoms occurred. No early deaths occurred during the CAG regimen.

Among the 33 patients achieving CR after the CAG regimen, 22 patients successfully bridged to allo-HSCT, and 11 patients received chemotherapy-based postremission treatments. In the patients who successfully bridged to allo-HSCT...
and the patients who received chemotherapy-based post-remission treatments, the estimated 2-year OS rates were 84.2% (95% CI, 47.0%-96.2%) and 58.3% (95% CI, 18.0%-84.4%) \((P = .095)\), respectively; the estimated 2-year EFS were 78.7% (95% CI, 43.2%-93.4%) and 58.3% (95% CI, 9.3%-68.8%) \((P = .012)\), respectively (Figure 4).

### Table 1

| Characteristic                        | Value          |
|--------------------------------------|----------------|
| Age, y                               | 31(15-78)      |
| Male sex -no. (%)                    | 28(68)         |
| Pretreatment                         |                |
| White blood cell count (×10⁹/L)      | 18.8 (0.9-310.8) |
| Platelet count (×10⁹/L)              | 95 (7-295)     |
| Blasts of bone marrow (%)            | 81 (21-99)     |
| Immunophenotyping                    |                |
| ETP                                  | 26(63.4)       |
| Early non-ETP                        | 6(14.6)        |
| Thymic                               | 6(14.6)        |
| Mature                               | 3(7.3)         |
| Cytogenetics-no (%)                  |                |
| Normal                               | 24(58.5)       |
| Complex                              | 6(14.6)        |
| Others                               | 11 (26.8)      |
| Risk                                 |                |
| Standard-risk                        | 163 (60-429)   |
| High-risk                            | 14 (34.2)      |
| Status before CAG regimen            |                |
| Refractory                           | 31             |
| 1 Prior course                       | 22             |
| 2 Prior courses                      | 6              |
| 3 Prior courses                      | 3              |
| Relapsed                             | 10             |
| 1 Prior salvage                      | 2              |
| 2 Prior salvage                      | 1              |
| No prior salvage                     | 7              |
| Status after CAG regimen             |                |
| CR-no (%)                            | 33 (80.5)      |
| PR-no (%)                            | 2 (4.9)        |
| NR-no (%)                            | 6 (14.6)       |
| ORR-no (%)                           | 35 (84.9)      |
| MRD-<0.1% after CAG regimen          | 12 (29.2)      |
| MRD->0.1% after CAG regimen          | 29 (70.8)      |

Note: High risk was defined as WBC counts higher than 100 x 10⁹/L or complex karyotype at the time of newly diagnosis and others was defined as standard risk. ORR was defined as CR plus PR.

Abbreviations: ETP, early T-cell precursors; MRD, minimal residual disease detected by flow cytometry.

### DISCUSSION

Adult patients with R/R-T-ALL have poor outcomes. As such, a novel therapy is urgently needed. Our multicenter results show that the CAG regimen is associated with a high CR rate of 80.5% and is well-tolerated, enabling most patients to bridge to allo-HSCT. Thus, this regimen represents a novel option for adult R/R-T-ALL patients. These promising results prompted a prospective multicenter trial that was initiated in June 2019 in China (Chinese Clinical Trial Registry number, ChiCTR1900023581).

The most interesting finding of this study, which included a relatively large sample size of patients from multiple centers in China, was the very high ORR rate (85.4%) associated with the use of the CAG regimen for R/R-T-ALL patients, confirming the previous results found in studies with smaller sample sizes from single centers. The CAG regimen is commonly and exclusively used for R/R-AML or elderly AML patients in Asia because aclarubicin has not been launched in America and Europe. Empirically, one group in China found an unexpectedly promising primary result in which all six R/R-T-ALL patients diagnosed from April 2004 to July 2006 achieved CR. Subsequently, the same group extended the treatment to another five patients, four of whom achieved CR. Commonly used salvage regimens for R/R-T-ALL include FLAG-based or hyper-CVAD-based regimens, which have CR rates varying from 30% to 50%. The only single-target drug for T-ALL is nelarabine, which has a CR rate varying from 31% to 36% as salvage monotherapy. A recent study from the Children's Oncology Group showed that the proteasome inhibitor bortezomib plus chemotherapy could increase the CR rate to 68% among 22 patients with once-relapsed T-ALL. According to the reported CR rates listed in Table 3, the CAG regimen seems to be a good salvage regimen for R/R-T-ALL, but the results should be interpreted cautiously for different eligible populations.

Good safety is another advantage of the CAG regimen for R/R-T-ALL according to its low hematological or nonhematological adverse events, which is in accordance with previous reports not only in T-ALL but also in AML. FLAG and hyper-CVAD have early death rates of 5%-20% and 3%-15%, respectively, and infection rates of 20% to 60%. Infections of grade 3-4 occurred in 58% of patients during treatment with the CAG regimen in our study, which was similar to other regimens. However, no early deaths (within 1 month) occurred in our study. Novel treatments, such as nelarabine and bortezomib, have the adverse event of neuropathy at a rate of up to 37%, which limits their repetitive use. However, no patients experienced neuropathy during treatment with the CAG regimen. The favorable safety of the CAG regimen is due to the low doses of araC and aclarubicin plus the use of G-CSF without using steroids. Previous studies have demonstrated that G-CSF has the
potential to promote the recovery of neutrophils and an enhanced ability to kill phagocytized bacteria,\textsuperscript{32,33} which may partially explain the safety of the CAG regimen.

A high percentage (66%) of patients successfully bridged to allo-HSCT, translating into promising survival outcomes in our study, while previous studies have shown only 9.1% to 26.9% of patients bridging to allo-HSCT (Table 3).\textsuperscript{7-18} The higher CR rate and lower toxicity of the CAG regimen allow more patients to rapidly proceed to HSCT; this is especially true for R/R-ETP-ALL patients, who would otherwise die

| TABLE 2 | Incidence of hematological and nonhematological toxic effects during CAG reinduction treatment |
|---------------------------------|--------------------------------------------------|
| Adverse Event | No. of patients | All grades |
|----------------|-----------------|------------|
|                 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | No. of patients | % |
| Hematologic     |         |         |         |         |                   |   |
| Neutropenia     | 2       | 7       | 4       | 26      | 39                | 95 |
| Anemia          | 1       | 8       | 9       | 21      | 41                | 100|
| Thrombocytopenia| 1       | 4       | 2       | 30      | 37                | 90 |
| Nonhematologic  |         |         |         |         |                   |   |
| Infection       | 1       | 2       | 23      | 1       | 27                | 66 |
| Nausea          | 17      | 3       | 0       | 0       | 20                | 49 |
| Vomiting        | 10      | 10      | 0       | 0       | 20                | 49 |
| Hemorrhage      | 13      | 1       | 0       | 0       | 14                | 34 |
| Cardiac         | 12      | 1       | 0       | 0       | 13                | 32 |
| Mucositis       | 9       | 2       | 1       | 0       | 12                | 29 |
| Raised liver ALT/AST | 5       | 1       | 1       | 0       | 7                 | 17 |
| Thrombosis/embolism | 6       | 0       | 0       | 0       | 6                 | 15 |
| Diarrhea        | 2       | 1       | 0       | 0       | 3                 | 7  |
| Headache        | 1       | 1       | 0       | 0       | 2                 | 5  |
| Hyperbilirubinemia | 2       | 0       | 0       | 0       | 2                 | 5  |
| Rash            | 1       | 0       | 0       | 0       | 1                 | 2  |
| Raised creatinine | 0      | 0       | 0       | 0       | 0                 | 0  |

Abbreviation: ALT, alanine transaminase; AST, aspartate aminotransferase.
within 6 months.\textsuperscript{23,24} As shown in our study, of the 26 R/R-ETP-ALL patients, 14 successfully bridged to allo-HSCT after achieving CR, which contributed to the similarly promising outcomes of these ETP-ALL patients compared with those of the non-ETP-ALL patients.

There were some limitations in our study. First, this was a one-arm trial rather than a randomized study, although we provided a mini-review of the historical literature. Given the rarity of R/R-T-ALL, it is unlikely that large randomized studies in adult patients will be undertaken to examine the question of which regimen is best for salvage therapy. We have initiated a prospective multicenter trial that will include 18 centers in China to validate this study. Second, the mechanism by which the CAG regimen affects T-ALL cells remains

| Reference   | Study resource               | Children/  | Relapse/  | No. of T-ALL patients | Reinduction regimen | CR, % | ED, % | Bridge HSCT, % | EFS, % | OS, % |
|-------------|------------------------------|------------|----------|-----------------------|---------------------|-------|-------|----------------|-------|-------|
| Rivera 2005\textsuperscript{7} | St. Jude Children's Research Hospital | Children | First relapse | 20 | Chemotherapy | 60 | 15 | 5.0 (5y) | 5.0 (5y) |
| Berg 2005\textsuperscript{8} | COG study | Children | Refractory/ relapse | 106 | Nelarabine | 25.7 | 0.7 | 5.0 (4y) |
| Fielding 2007\textsuperscript{9} | MRC UKALL12/ECOG 2993 study | Adult | First relapse | 92 | Chemotherapy | 31 | 0 | 26.9 | 28(1y) |
| DeAngelo 2007\textsuperscript{10} | CALGB-19801 study | Adult | Refractory/ relapse | 26 | Nelarabine | 31 | 0 | 26.9 | 28(1y) |
| Raetz 2008\textsuperscript{11} | COG-AALL01P2 study | Children | First relapse | 7 | Chemotherapy | 28.8 | 0(5y) | 0(5y) |
| Reismüller 2009\textsuperscript{12} | Austria-BFM-study | Children | First relapse | 28 | Chemotherapy | 36 | 0.8 | 28.6 | 21(10y) |
| Marks 2009\textsuperscript{13} | UKALL XII/ECOG 2993 study | Adult | First relapse | 123 | Chemotherapy | 43 | 22 | 22.5(4y) |
| Gökbüget 2011\textsuperscript{14} | German Multicenter Study Group | Adult | Refractory/ relapse | 126 | Nelarabine | 36 | 0.8 | 28.6 | 11(6y) |
| O’Brien 2013\textsuperscript{15} | Multi-Centre of USA and Canada | Adult | Refractory/ relapse | 10 | Incristine Sulfate Liposome | 20 | 12 | 10 |
| Horton 2019\textsuperscript{16} | COG AALL07P1 Study | Children | First relapse | 22 | Bortezomib + Chemo | 68 | 202 | 43(3y) (CR2) | 43(3y) (CR2) |
| Xue 2013\textsuperscript{21} | Soochow University | Children | Refractory/ relapse | 41 | CAG regimen | 80.5 | 0 | 66 | 56.5(2y) |

\textbf{TABLE 3} Salvage regimens for refractory or relapsed T-ALL.
unclear, although a previous study found that T-ALL cells highly express G-CSF receptors, and G-CSF has a synergetic effect in eliminating T-ALL cells when administered simultaneously with araC and aclarubicin.\textsuperscript{34} Moreover, 24 of 33 refractory patients in our study received only one prior induction regimen, which may introduce a bias and make it difficult to extend our findings to heavily treated patients.

In summary, our multicenter results show that the CAG regimen is highly effective and well-tolerated in adult patients with R/R-T-ALL. The CAG regimen enabled most patients to successfully bridge to allo-HSCT and achieve improved outcomes; thus, it represents a novel option for this population with poor prognosis.

**CONFLICT OF INTEREST**

We declare no competing interests.

**AUTHOR CONTRIBUTORS**

H-HZ, JH, and JJ drafted the manuscript and contributed to the final draft; and others collected data of the manuscript; and all authors reviewed and approved the final draft.

**ACKNOWLEDGMENTS**

This work was supported by grants from the National Natural Science Foundation of China (81570128 and 81820108004).

**ORCID**

Xiaoxia Hu \(\text{https://orcid.org/0000-0002-2719-3805}\)
Juan Du \(\text{https://orcid.org/0000-0003-2538-4007}\)
Jie Jin \(\text{https://orcid.org/0000-0002-8166-9915}\)
Hong-Hu Zhu \(\text{https://orcid.org/0000-0003-2343-0436}\)

**REFERENCE**

1. Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134-1142.
2. Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. *Hematology*. 2016;2016(1):580-588.
3. Hefazi M, Litzow MR. Recent advances in the biology and treatment of T cell acute lymphoblastic leukemia. *Curr Hematol Malig Rep*. 2018;13(4):265-274.
4. Frey NV, Luger SM. How I treat adults with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic leukemia. *Blood*. 2015;126(5):589-596.
5. Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed/refractory acute lymphoblastic leukemia. *Clin Adv Hematol Oncol*. 2019;17(3):166-175.
6. McMahon CM, Luge SM. Relapsed T cell all: current approaches and new directions. *Curr Hematol Malig Rep*. 2019;14(2):83-93.
7. Rivera GK, Zhou Y, Hancock ML, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. *Cancer*. 2005;103(2):368-376.
8. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. *Clin Oncol*. 2005;23(15):3376-3382.
9. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. *Blood*. 2007;109(3):944-950.
10. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and Leukemia Group B study 19801. *Blood*. 2007;109(12):5136-5142.
11. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: a Children’s Oncology Group Study. *J Clin Oncol*. 2008;26(24):3971-3978.
12. Reis unmiller B, Attarbaschi A, Peters C et al Long-term outcome of initially homogeneously treated and relapsed childhood acute lymphoblastic leukemia in Austria–a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. *Br J Haematol*. 2009;144(4):559-570.
13. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood*. 2009;114(25):5136-5145.
14. Gökbüget N, Basara N, Baummann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. *Blood*. 2011;118(13):3504-3511.
15. O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. *J Clin Oncol*. 2013;31(6):676-683.
16. Horton TM, Whitlock JA, Lu X, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group. *Br J Haematol*. 2019;186(2):274-285.
17. Specchia G, Pastore D, Carluccio P, et al. FLAG-IDA in the treatment of refractory/refractory adult acute lymphoblastic leukemia. *Ann Hematol*. 2005;84:792-795.
18. Hijjya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. *Blood*. 2011;118:6043-6049.
19. Wei G, Ni W, Chiao JW, Cui Z, Huang H, Liu D. A meta-analysis of clofarabine (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. *J Hematol Oncol*. 2013;6:46.
20. Xue SL, Wu DP, Sun AN, Tang XW, CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. *Am J Hematol*. 2008;83(2):167-170.
21. Xue S-L, Cui H-X, Zou J-Y, et al. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients. *Hematol Oncol*. 2013;31(4):206-212.
22. Liu L, Jiao W, Zhang Y, et al. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. *Leuk Res*. 2015;39(3):323-328.
23. Coustan-Smith E, Mullighan CG, Onciu M, et al. T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-156.

24. Jain N, Lamb AV, O’Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863-1869.

25. NCCN. National Comprehensive Cancer Network Acute lymphoblastic leukemia version 2. 2019. Accessed May 15, 2019.

26. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-4649.

27. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.

28. Montillo M, Tedeschi A, Centurioni R, Leoni P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma. 1997;25(5–6):579-583.

29. Yavuz S, Paydas S, Disel U, Sahin B. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther. 2006;13(5):389-393.

30. Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia. 1997;11(12):2039-2044.

31. Faderl S, Thomas DA, O’Brien S, et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011;11(1):54-59.

32. Welte K. G-CSF: filgrastim, lenograstim and biosimilars. Expert Opinion on Biological Therapy. 2014;14(7):983-993.

33. Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med. 1987;165(4):941-948.

34. Wu YL, Xue SL, Sun AN, et al. Mechanism of CAG regimen eliminating T-cell acute lymphoblastic leukemia A3 cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16(6):1279-1282.

How to cite this article: Qian J-J, Hu X, Wang Y, et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. Cancer Med. 2020;9:5327–5334. https://doi.org/10.1002/cam4.3079